intracellular sigma peptide

Intracellular sigma peptide is a cell-penetrant therapeutic peptide designed as a mimetic of the intracellular wedge domain of the receptor protein tyrosine phosphatase sigma (PTPσ), the principal neuronal receptor for chondroitin sulfate proteoglycans (CSPGs) in the inhibitory extracellular matrix after nervous system injury. By competitively binding to the intracellular domain of PTPσ, ISP disrupts CSPG–PTPσ signaling, normalizes downstream pathways such as ERK1/2, and relieves CSPG-mediated inhibition of axon growth, thereby promoting axonal regeneration, remyelination, neuromuscular junction repair, and functional recovery in preclinical models of spinal cord injury, spinal root avulsion, brachial plexus injury, and demyelination.[1][7][8][2] The peptide is conjugated to a TAT (trans-activator of transcription) sequence to enable systemic administration and efficient membrane penetration, including across the blood–brain barrier, and is being developed as a regenerative therapy for central and peripheral nervous system damage by academic investigators and NervGen Pharma.

Other names

ISPIntracellular Sigma Peptide